Chronic myelogenous leukemia: molecular monitoring in clinical practice

Chronic myelogenous leukemia: molecular monitoring in clinical practice

Show other versions (1)

Use of tyrosine kinase inhibitor imatinib has led to significant progress in chronic myeloid leukemia (CML) treatment. To date, genetic monitoring is a mandatory attribute of therapy with tyrosine kinase inhibitors. The purpose of this study was to access the imatinib therapy efficacy in CML patient...

Full description

Bibliographic Details
Main Authors: N. R. Ryabchikova, I. R. Minniakhmetov, G. Sh. Safuanova, D. V. Islamgulov, A. S. Karunas, E. E. Khusnutdinova
Format: Article
Language:Russian
Published: ABV-press 2014-07-01
Series:Онкогематология
Subjects:
chronic myeloid leukemia
molecular genetic monitoring
ph-positive cells mutations
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/39

Similar Items

Similar Items